lipedema and glp-1 Tirzepatide as a Potential Disease-Modifying Therapy in Lipedema: A Narrative Review on Bridging Metabolism, Inflammation, Fibrosis GLP-1 & “lumpy texture” :

This review study analyzes human GLP-1 trials, including protocols via injection that may be considered low dose or microdosing

To address this gap, we previously developed a two-session operant food intake paradigm with four meal schedule conditions assigned on a weekly basis

Association between diabetes, obesity, aging, and cancer: Review of recent literature

A physician review of the resM formulation noted that the specific doses of these nutrients warrant consideration in patients with underlying kidney conditions

Standard disclaimer: Im a physician, but Im not your physician

In the AWARD-1 trial, rates were consistent across groups, including placebo (4% dulaglutide 1.5 mg, 5% dulaglutide 0.75 mg, 4% exenatide and 4% placebo), and URIs were not reported in the GetGoal-X or the AWARD-6 trials